# Medpace Holdings Inc. (MEDP) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $591.29, market value $16.5 billion.

## Valuation
- **P/E (trailing): 34.7×** (5-yr avg 34.4×, 3-yr avg 32.5×). Medpace Holdings Inc. trades at 34.7× trailing earnings, close to its own five-year average of 34.4×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 30.6×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.46**. A PEG of 1.46 is in the range usually read as fairly priced for its growth.
- **Price / sales: 5.9×**. Each dollar of revenue is priced at 5.9×.
- **Price / book: 38.0×**. The shares trade at 38.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 26.2×**. Enterprise value is 26.2× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 4.3%** (5-yr avg 4.3%). Free cash flow equals 4.3% of the market value, in line with its five-year average of 4.3%.
- **Earnings yield: 2.9%**. The inverse of the P/E: 2.9% of the price is earned each year.

## Profitability
- **Operating margin: 21.0%**. 21.0% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 17.8%**. 17.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 98.3%**. A 98.3% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on assets: 24.9%**. Each dollar of assets produces 24.9% of profit.

## Growth
- **Revenue growth (1 yr): 20.0%** (3-yr 20.1%/yr, 5-yr 22.3%/yr). Revenue grew 20.0% over the last year, against 22.3% a year compounded over five years.
- **EPS growth (1 yr): 21.0%** (3-yr 28.0%/yr, 5-yr 31.8%/yr). Earnings per share rose 21.0%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 24.8%/yr**. Free cash flow has compounded at 24.8% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Medpace Holdings Inc. holds more cash than debt.
- **Current ratio: 0.74** (quick 0.74). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 8.81**. A Z-score of 8.81 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 7/9**. 7 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. Medpace Holdings Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 22.6%** (YTD 5.3%, 3-mo 30.2%). The shares are up 22.6% over twelve months including dividends.
- **From 52-week high: -12.8%** (58.5% above the low). Trading 13% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 0.78** (volatility 45%). Beta of 0.78 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MEDP · Page: https://foliofundamentals.com/stocks/medp

Not investment advice.